A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C not responding to interferon alone

Hepatology

Volumn 34, Issue 1, 2001, Pages 133-138

  Saracco, Giorgio ^a   Ciancio, Alessia ^a   Olivero, Alda ^a   Smedile, Antonina ^a   Roffi, Luigi ^b   Croce, Guido ^c   Colletta, Cosimo ^d   Cariti, Giuseppe ^e   Andreoni, Massimo ^f   Biglino, Alberto ^g   Calleri, Guido ^e   Maggi, Giovanni ^h   Tappero, Gian Franco ⁱ   Orsi, Pier Giulio ^j   Terreni, Natalia ^k   Macor, Antonio ^e   Di Napoli, Angelo ^l   Rinaldi, Enrico ^m   Ciccone, Giovannino ^a   Rizzetto, Mario ^a  

^a MOLINETTE HOSPITAL   (Italy)

^b Ospedale Generale Provinciale   (Italy)

^c SAN CARLO BORROMEO HOSPITAL   (Italy)

^d Ospedale Madonna del Popolo   (Italy)

^e AMEDEO DI SAVOIA HOSPITAL   (Italy)

^f OSPEDALE DEGLI INFERMI   (Italy)

^g Ospedale Civile   (Italy)

^h UTIN Ospedale Fatebenefratelli   (Italy)

ⁱ GRADENIGO HOSPITAL   (Italy)

^j C Arrigo Children's Hospital   (Italy)

^k VALDUCE HOSPITAL   (Italy)

^l S GIOVANNI BOSCO HOSPITAL   (Italy)

^m SANT ANNA HOSPITAL   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; RIBAVIRIN;

ADULT; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS C; HISTOPATHOLOGY; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0034955579     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2001.25636     Document Type: Article

References (28)

1. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
2. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
3. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C
4. EASL International Consensus Conference on Hepatitis C Paris, 26-28, February 1999, Consensus Statement
5. Management of hepatitis C
6. Efficacy of a second cycle of interferon therapy in patients with chronic hepatitis C
7. Pilot study of a short course of ribavirin and alpha interferon in the treatment of chronic active hepatitis C not responding to alpha-interferon alone
8. Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: Results of a randomized, controlled trial
9. A randomized trial of ribavirin and interferon-alfa versus interferonalfa alone in patients with chronic hepatitis C who were non-responders to a previous treatment
10. Retreatment of non-responders or relapser chronic hepatitis C patients with interferon plus ribavirin vs interferon alone
11. Interferon alpha plus ribavirin in chronic hepatitis C resistant to previous interferon-alfa course: Results of a randomized multicenter trial
12. Definition of response to antiviral therapy in chronic hepatitis C
13. Histological grading and staging of chronic hepatitis
14. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C
15. Ribavirin and lymphoblastoid alfa-interferon vs alfa-interferon alone in the retreatment of chronic hepatitis C: A randomized clinical trial
16. Combination antiviral therapy with ribavirin and interferon alpha in interferon alpha relapsers and non responders: Italian experience
17. Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: Analysis of individual patient data of six controlled trials
18. Interferon and Ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy: A meta-analysis of controlled and uncontrolled trials
19. Interferon-alfa2b and ribavirin in combination for chronic hepatitis C patients not responding to interferon-alfa alone: An Italian multicenter, randomized, controlled, clinical study
20. A comparison of three interferon alfa2b regimens for long term treatment of chronic non-A non-B hepatitis
21. Reinforced regimen of interferon alfa-2a reduces the incidence of cirrhosis in patients with chronic hepatitis C: A multicenter randomised trial
22. Effects of interferon therapy in "non responder" patients with chronic hepatitis C
23. Is an "à la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C?
24. Antiviral therapy of patients with chronic hepatitis C
25. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C
26. Peginterferon alfa-2a in patients with chronic hepatitis C
27. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis
28. Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C